EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company backed by EQT Life Sciences, closed 8.4% below its IPO price in its trading debut Friday after the firm raised $200 million in a listing.
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company backed by EQT Life Sciences, closed 8.4% below its IPO price in its trading debut Friday after the firm raised $200 million in a listing.
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
